Relationship Between The Expression Of Vasohibin1 And The Prognosis In Patients With Stage ? Gastric Cancer

[Objective]To explore the relationship between various clinical features,postoperative adjuvant chemotherapy and prognosis in patients with stage III gastric cancer.The expression level of vasohibin1(VASH1)in stage III gastric cancer tissues was analyzed,and its relationship with prognosis was explored.[Methods]A retrospective analysis of clinically pathological features and postoperative treatment was performed in patients who underwent radical gastrectomy in our hospital from January 2009 to December 2014 and whose pathology was confirmed as stage III.The correlationship between clinical features,postoperative treatment and prognosis were counted.The postoperative tumor tissues and paracancerous histopathological sections were collected and immunohistochemical staining was performed to analyze the expression of VASH1 in the tumor tissues of the above patients.The SPSS 22.0 software package was used to analyze the correlation between expression levels of the above factors and their clinical characteristics and survival.[Results]1.A total of 204 patients with stage III gastric cancer were enrolled.The median follow-up time was 86.0 months.At the end of follow-up,on September 1,2018,a total of 147 patients had recurrence and metastasis(72.1%)and 139 died(68.1%).The mDFS 17.1 months,1,2,3 years disease-free survival rate were 60.4%,42.1%,35.6%,mOS 35.8 months,1,2,3 years overall survival rate were 85.3%,61.3%,49.5%.COX regression analysis showed that Lauren classification,Borrmann classification and clinical stage were independent prognostic factors of mDFS.Tumor location,presence of cancer nodules and clinical stage were independent prognostic factors of mOS.2.Compared with the docetaxel group(n=118),the oxaliplatin-based chemotherapy group(n=60)had a median DFS of 21.6 months and 13.0 months(P=0.109),and the median OS was 35.7 months and 35.0 months,respectively.The difference was not statistically significant.Among patients with stage ? gastric cancer who were treated with oxaliplatin,mDFS in the XELOX group(n=79)and the control group(n=39)containing the SOX and mFOLFOX6 regimens were 23.5 months and 16.0 months,respectively(P=0.116),and mOS was 37.5 months and 35.2 months,respectively(P=0.153).There was no statistically significance neither.The disease-free survival time of the XELOX regimen was prolonged between different chemotherapy groups,although there was no statistical difference,the survival curve was isolated.3?The positive rate of VASH1 expression in tumor tissues of all 204 patients was 59.3%,which was significantly higher than that of adjacent tissues(33.7%)(P<0.05).VASH1-positive patients had a worse prognosis than the patients with negative expression(mDFS:15.0 vs.25.5 months,P=0.028;mOS:28.1 vs.52.9 months,P=0.002).VASH1 was an independent prognostic factor for disease-free survival and overall survival.[Conclusion]Lauren classification,Borrmann classification,clinical stage and VASH1 expression are independent prognostic factors of mDFS.Tumor location,presence of cancer nodules,VASH1 expression level and clinical stage are independent prognostic factors of mOS.There was no significant difference in the effects of different chemotherapy regimens on DFS and OS in patients with stage ? gastric cancer.